Dated: February 26, 1998.

Jeanette C. Takamura,

Assistant Secretary for Aging.

[FR Doc. 98–5740 Filed 3–4–98; 8:45 am]

BILLING CODE 4150–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Availability of Annual Reports

In accordance with section 13 of the Federal Advisory Committee Act, as amended (5 U.S.C. App. 2), (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) gives notice that annual reports for the following CDC Federal advisory committees have been filed with the Library of Congress:

Advisory Committee for Injury Prevention and Control Injury Research Grant Review Committee

Copies of these reports are available to the public for inspection at the Newspaper and Current Periodical Reading Room, Room LM 133, Madison Building, Library of Congress, 101 Independence Avenue, SE, Washington, DC 20540–4760, telephone 202/707–5690. Additionally, on weekdays between 8 a.m. and 4:30 p.m., copies will be available for inspection at the Management Analysis and Services Office, Committee Management and Program Panels Activity, CDC, 4 Executive Park Drive, Suite 1117, Atlanta, Georgia 30329, telephone 404/639–6389. Copies may also be obtained by writing to the CDC Committee Management and Program Panels Activity (MS E–72), 1600 Clifton Road, NE, Atlanta, Georgia 30333.

Dated: February 27, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–5665 Filed 3–4–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30DAY–09–98]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639–7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice.

Proposed Projects

1. National Exposure Registry (0923–0006)—Revision

The information collected is part of the Agency for Toxic Substances' ongoing National Exposure Registry (NER)—a database composed of a listing of persons, along with health and demographic information, with documented exposure to selected toxic substances subregistries). The NER was created in response to a Congressional Superfund mandate to create a registry of persons with exposure to hazardous substances and a registry of persons with illness or health problems as a result of exposure to hazardous substances. The mandate was created because there is little or no information available about the potential health effects of low-level, long-term exposure to hazardous substances on a general population—such as is found at waste sites. Unlike most occupationally exposed populations, this environmentally-exposed population has extremely vulnerable components such as pregnant women, the elderly, those with compromised health, and children.

Since the adverse health effects are not known, neither is the latency period for the potential health effects. Therefore, the NER is a longitudinal project: a baseline and biennial follow-ups that will continue until all parties involved agree the established criteria for ending that chemical specific subregistry have been met. The questionnaire is administered (usually in a personal interview) at baseline; the same questionnaire is administered (using computer assisted interviews) to each registrant longitudinally. The data is compared to national norms at each collection and intrafile comparisons are made over multiple collections. Other than their time to participate, there is no cost to respondents. The period requested is for 3 years. Total average annual burden hours are 5,833.33.

Year	Number of registries	Total Number of respondents	Responses per respondent	Total responses	Hrs. per respondent	Total burden (in hrs.)
Year 1	0 updates, 1 new	13,000	1	13,000	0.5	6,500
Year 2	1 update, 0 new	13,000	1	13,000	0.5	6,500
Year 3	4 updates, 0 new	9,000	1	9,000	0.5	4,500

2. Information Collection To Establish Community Assistance Panels (CAPs)—(0923–0007); Extension

The Agency for Toxic Substances and Disease Registry (ATSDR) is mandated pursuant to the 1980 Comprehensive Environmental Response Compensation and Liability Act (CERCLA), and its 1986 Amendments, The Superfund Amendments and Reauthorization Act (SARA), to prevent or mitigate adverse human health effects and diminished quality of life resulting from the exposure to hazardous substances into the environment. To facilitate this effort, ATSDR seeks the cooperation of the community being evaluated through direct communication and interaction. Direct community involvement is required to conduct a comprehensive scientific study and to effectively disseminate specific health information in a timely manner. Also, this direct interaction fosters a clear understanding of health issues that the community considers to be of importance and establishes credibility for the agency. The Community Assistance Panel nominations forms are completed by individuals in the community to nominate themselves or others for participation on these panels. Other than the possible cost of a postage stamp, there is no cost to respondents. This request is for a 3-year extension of the current OMB approval of the Community Assistance Panel nominations form. Total annual burden hours are 200.

Respondents	Number of respondents	Number of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
General Public	1200	1	.1666	200

3. X-Ray Examination Program—(0920–0020)—Extension

The X-ray Examination Program is a federally mandated program under the Federal Mine Safety and Health Act of 1977, PL–95–164. The Act provides the regulatory guidance for the administration of the National Coal Workers' X-ray Surveillance Program, a surveillance program to protect the health and safety of underground coal miners. This program requires the gathering of information from coal mine operators, participating miners, participating x-ray facilities and participating physicians. The Appalachian Laboratory for Occupational Safety and Health (ALOSH), National Institute for Occupational Safety and Health (NIOSH) is charged with administration of this program. Total annual burden hours are 4,791.

Form title	Total of respondents	Responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Roentgenographic Interpretation Title 42 CFR 37.40 (b) 37.50(a); 37.60(a)	20,000	1	0.05	1,000
Miner Identification Title 42 CFR 37.20 37.40(b); 37.60(a)	10,000	1	0.333	3,333
Coal Mine Operator Plan Title 42 CFR 37.4(a)	500	1	0.5	250
Facility Certification Title 42 CFR 37.42(c)	300	1	0.5	150
Interpreting Physician Certification Title 42 CFR 37.51(c)	350	1	0.1666	58

Dated: February 24, 1998.

Kathy Cahill,

Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–5662 Filed 3–4–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Dermatologic and Ophthalmic Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on March 19 and 20, 1998, 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn, Walker Room, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Tracy Riley or Angie Whitacre, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12534. Please call the Information Line for up-to-date information on this meeting.

Agenda: On March 19, 1998, the committee will discuss generic topical dermatologicals draft guidance. On March 20, 1998, the committee will participate in a scientific discussion of clinical trial design questions for products intended for the treatment of psoriasis.

Procedure: On March 19, 1998, from 8:30 a.m. to 1 p.m., and on March 20, 1998, from 8:30 a.m. to 5:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be made to the contact person by March 11, 1998. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9 a.m., on March 19 and 20, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 13, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On March 19, 1998, from 1 p.m. to 5:30 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). This portion of the meeting will be closed to permit discussion on pending investigational new drug applications issues.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: February 25, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–5630 Filed 3–4–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N–0309]

Agency Information Collection Activities; Announcement of OMB Approval

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Infant Formula Requirements'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 19, 1997